Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

BACKGROUND: In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, A T, Riely, G J, Bang, Y -J, Kim, D -W, Camidge, D R, Solomon, B J, Varella-Garcia, M, Iafrate, A J, Shapiro, G I, Usari, T, Wang, S C, Wilner, K D, Clark, J W, Ou, S -H I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/
https://www.ncbi.nlm.nih.gov/pubmed/30980071
http://dx.doi.org/10.1093/annonc/mdz131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/
https://www.ncbi.nlm.nih.gov/pubmed/30980071
http://dx.doi.org/10.1093/annonc/mdz131

Ejemplares similares